Measuring albuminuria in patients with hypertension, CKD, or diabetes helps identify those at increased cardiovascular risk who may benefit from cardioprotective treatments.
Does screening for albuminuria help evaluate cardiovascular risk in patients with cardio-kidney-metabolic syndrome?
Albuminuria screening is recommended in patients with hypertension, CKD, or diabetes to identify those who may benefit from cardioprotective treatments.
Absolute Event Rate: 0% vs 0%
Cardio-kidney-metabolic (CKM) syndrome combines cardiac, renal, and metabolic impairments. Albuminuria, as measured by the urine albumin-to-creatinine ratio, is a biomarker of endothelium-glomerular damage present in CKM syndrome. The gold standard method is quantitative measurement using an immunoenzymatic technique in a laboratory. Albuminuria is continuously associated with cardiovascular risk, even when the increase is modest. The improvement in cardiovascular prognosis achieved with treatments that reduce albuminuria suggests that CKM syndrome is reversible through multiple mechanisms. It is recommended measuring albuminuria in patients with arterial hypertension, chronic kidney disease, or diabetes, and then identifying those who may benefit from cardioprotective treatment.
Akiba et al. (Thu,) reported a other. Measuring albuminuria in patients with hypertension, CKD, or diabetes helps identify those at increased cardiovascular risk who may benefit from cardioprotective treatments.